Efficacy of levomilnacipran extended release in treating major depressive disorder.

about

Efficacy of levomilnacipran extended release in treating major depressive disorder.

Item

http://www.wikidata.org/entity/Q47303967

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efficacy of levomilnacipran extended release in treating major depressive disorder.

@en

Efficacy of levomilnacipran extended release in treating major depressive disorder.

@nl

type

Item

label

Efficacy of levomilnacipran extended release in treating major depressive disorder.

@en

Efficacy of levomilnacipran extended release in treating major depressive disorder.

@nl

prefLabel

Efficacy of levomilnacipran extended release in treating major depressive disorder.

@en

Efficacy of levomilnacipran extended release in treating major depressive disorder.

@nl

P1476

Efficacy of levomilnacipran extended release in treating major depressive disorder.

@en

P2093

Peter T Ho

http://www.w3.org/2001/XMLSchema#string

Renee-Marie Ragguett

http://www.w3.org/2001/XMLSchema#string

Roger S McIntyre

http://www.w3.org/2001/XMLSchema#string

Samantha J Yim

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

Cross-national epidemiology of DSM-IV major depressive episode.

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Descriptive epidemiology of major depressive disorder in Canada in 2012.

Disposition and metabolism of [14C]-levomilnacipran, a serotonin and norepinephrine reuptake inhibitor, in humans, monkeys, and rats.

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans

Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients.

Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.

P304

2017-2024

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1410540

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29195487

http://www.w3.org/2001/XMLSchema#string